Let’s talk crypto, Metaverse, NFTs, CeDeFi, and Stocks, and focus on multi-chain as the future of blockchain technology. Haha, Take it easy. Let us all WIN!
Tandem Diabetes Care Inc reported its financial year results and Q4 earnings. Although the company reported profits, TNDM stock went down as the sales continued to slag.
Tandem Diabetes Care Inc (NASDAQ: TNDM) unexpectedly posted profits in the fourth quarter on Monday. After that, the stocks took a downtrend direction and dipped below to trade at 78.30 at the time of writing. It means that TNDM is around 10% today. In the framework of its Q4 report, Tandem Diabetes also announced the 2019 full-year financial results and the 2020 financial guidance.
The leading insulin delivery company which also specializes in diabetes technology read out its full financial statement, which was not received well by the stock market. The shares used to be rising since the beginning of the year after breaking out of the strong hurdle that took the better part of 2019.
However, it is worth noting that despite the negative movement of the stocks on the shorter time frames, TNDM stocks have been revering since 2018 from the long free fall that they experienced from 2014. With the company reporting a positive financial statement, the shares are expected to recover soon and retest the all times high, which is above 300 units.
Details of Tandem Diabetes Q4 Financial Report
According to the report, in comparing the year that ended on December 31. 2019 to the same period in 2018, the worldwide pump shipments increased by 113% to about 73,431 pumps, which is up from 34,493 pumps. The sales increased by 97% from $183.9 billion to $362.3 billion.
Tandem Diabetes also recorded an increase in the gross margin, which increased from 49% to 54%. The report also indicated the adjusted EBITDA improved from negative eight percent to 13% of the sales.
The same report compared the Q4 of 2019 to that of the same period of 2018 for Tandem Diabetes. After analyzing, the worldwide pump shipment increased by 21% up from slightly above 16,000 pumps to 19,602 pumps.
Comparing further, the sales increased by 42% up from $76.2 million to $108.4 million. The gross margin was noted to have improved by 1 point from 55% to 66%, whereas, the adjusted EBITDA rose from 16% to 21%.
According to the president and chief executive officer of the company John Sheridan, in 2019, the company more than doubled its year-over-year shipments, primarily based on the strength of its basal-IQ technology adoption. He continued to say that, ‘we pioneered two new device categories with the FDA and received clearance for t: slim x2 with control-IQ technology, the most advanced automated insulin delivery system available’.
He concluded that the company is working to bring the benefits of its t:slim x2 system to more people suffering from diabetes worldwide in the year ahead.